<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:voc="urn:hl7-org:v3/voc" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0297a568-6dca-efb2-e5cb-2cd21891ef3e"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use TIGECYCLINE FOR INJECTION safely and effectively. See full prescribing information for TIGECYCLINE FOR INJECTION. <br/>TIGECYCLINE for injection, for intravenous use <br/>Initial U.S. Approval: 2005</title>
   <effectiveTime value="20250501"/>
   <setId root="230484a8-408c-dcc1-d0c4-d9dd9a46831b"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="845263701" root="1.3.6.1.4.1.519.1"/>
            <name>Apotex Corp</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="209429182" root="1.3.6.1.4.1.519.1"/>
                  <name>Apotex Inc</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="918601238" root="1.3.6.1.4.1.519.1"/>
                        <name>Gland Pharma Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="analysis"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-6098" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-6098" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="api manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-6098" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="860038013" root="1.3.6.1.4.1.519.1"/>
                        <name>Gland Pharma Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="api manufacture"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="60505-6098" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="c4bfecc4-a878-32b0-9743-20f1e4dd7030"/>
               <code code="48780-1" displayName="SPL PRODUCT DATA ELEMENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250501"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="60505-6098" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Tigecycline</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>TIGECYCLINE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="mL" value="5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="70JE2N95KR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TIGECYCLINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="70JE2N95KR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TIGECYCLINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="mL" value="5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-USE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="60505-6098-1"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20190409"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA204439" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190409"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <section>
                     <id root="9f135deb-17d1-6f9a-ff6a-dc6c8c3706b7"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <effectiveTime value="20160106"/>
                     <component>
                        <observationMedia ID="MM541912986681">
                           <text>tigecycline-for-injection-vial-label.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="tigecycline-for-injection-vial-label.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM446828213536">
                           <text>tigecycline-for-injection-carton-label.jpg</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="tigecycline-for-injection-carton-label.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_82173f5b-0994-30a3-4c1c-14fada0cf90b">
               <id root="0e108afd-9979-b564-2f17-fb577641a88e"/>
               <code code="34066-1" displayName="BOXED WARNING SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>
                  <content styleCode="bold">WARNING: ALL-CAUSE MORTALITY</content> <content styleCode="bold"/>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in tigecycline-treated patients versus comparator. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable </content>
                     <content styleCode="bold italics">[see Indications and Usage (<linkHtml href="#s6">1.4</linkHtml>), Warnings and Precautions (5.1, 5.2) and Adverse Reactions (6.1)]. </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: ALL-CAUSE MORTALITY </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics"> See full prescribing information for complete boxed warning. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">All-cause mortality was higher in patients treated with tigecycline for injection than comparators in a meta-analysis of clinical trials. The cause of this mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable </content>
                           <content styleCode="bold italics">(</content>
                           <content styleCode="bold italics">
                              <linkHtml href="#s6">1.4</linkHtml>, <linkHtml href="#_d7bcb6ac-c57a-2238-d878-73fbf33da1ea">5.1</linkHtml>, <linkHtml href="#s16">5.2</linkHtml>, <linkHtml href="#Gd3838ed3-f815-4394-b56c-5712b13e6a41">6.1</linkHtml>
                           </content>
                           <content styleCode="bold italics">).   </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_f745fa2d-02c7-3e9c-ec87-01205a5010bd">
               <id root="35b731bc-c945-1c71-db8e-4b202cb63b4b"/>
               <code code="43683-2" displayName="RECENT MAJOR CHANGES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>RECENT MAJOR CHANGES SECTION</title>
               <effectiveTime value="20250505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Contraindications (<linkHtml href="#s14">4</linkHtml>) 1/2025 <br/> Warnings and Precautions, Tetracycline-Class Adverse Effects (<linkHtml href="#s25">5.11</linkHtml>) 3/2025</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="60abb0ba-8466-d4d1-7781-e6b06bd7b198"/>
               <code code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20200728"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tigecycline for injection is a tetracycline class antibacterial indicated in patients 18 years of age and older for: </paragraph>
                        <list ID="Gf9068854-7b17-4541-a6cc-a72929339d8d" listType="unordered" styleCode="Disc">
                           <item>Complicated skin and skin structure infections (<linkHtml href="#s3">1.1</linkHtml>) </item>
                           <item>Complicated intra-abdominal infections (<linkHtml href="#s4">1.2</linkHtml>) </item>
                           <item>Community-acquired bacterial pneumonia (<linkHtml href="#s5">1.3</linkHtml>) </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use: </content>Tigecycline for injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia (<linkHtml href="#s6">1.4</linkHtml>).</paragraph>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs, tigecycline for injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria (<linkHtml href="#_753ed7ff-ca5a-082d-2562-97499426787c">1.5</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="G2135cbe8-42a5-47ab-a56b-291b0fb3f976">
                     <id root="7ce1c8d5-7428-a6a1-4e33-b3908b03e9e6"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.1 Complicated Skin and Skin Structure Infections </title>
                     <text>
                        <paragraph>Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of complicated skin and skin structure infections caused by susceptible isolates of <content styleCode="italics">Escherichia coli, Enterococcus faecalis</content> (vancomycin-susceptible isolates), <content styleCode="italics">Staphylococcus aureus</content> (methicillin-susceptible and -resistant isolates), <content styleCode="italics">Streptococcus agalactiae, Streptococcus anginosus</content> grp. (includes <content styleCode="italics">S. anginosus, S. intermedius,</content> and <content styleCode="italics">S. constellatus</content>), <content styleCode="italics">Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae,</content> and <content styleCode="italics">Bacteroides fragilis. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="5b8e2f28-eadc-6214-ab97-4ff786951ac1"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.2 Complicated Intra-abdominal Infections </title>
                     <text>
                        <paragraph>Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of complicated intra-abdominal infections caused by susceptible isolates of <content styleCode="italics">Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis</content> (vancomycin-susceptible isolates), <content styleCode="italics">Staphylococcus aureus</content> (methicillin-susceptible and ‑resistant isolates), <content styleCode="italics">Streptococcus anginosus</content> grp. (includes <content styleCode="italics">S. anginosus, S. intermedius,</content> and <content styleCode="italics">S. constellatus</content>), <content styleCode="italics">Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens,</content> and <content styleCode="italics">Peptostreptococcus micros.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="4cb83244-f6a2-2b9f-d450-09891e68689f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.3 Community-Acquired Bacterial Pneumonia</title>
                     <text>
                        <paragraph>Tigecycline for injection is indicated in patients 18 years of age and older for the treatment of community-acquired bacterial pneumonia caused by susceptible isolates of <content styleCode="italics">Streptococcus pneumoniae</content> (penicillin-susceptible isolates), including cases with concurrent bacteremia, <content styleCode="italics">Haemophilus influenzae</content>, and <content styleCode="italics">Legionella pneumophila</content>. </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="ddf639c3-e524-1bae-3dc7-b9e807dfc532"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.4 Limitations of Use </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Tigecycline for injection is not indicated for the treatment of diabetic foot infections. A clinical trial failed to demonstrate non-inferiority of tigecycline for injection for treatment of diabetic foot infections. Tigecycline for injection is not indicated for the treatment of hospital-acquired or ventilator-associated pneumonia. In a comparative clinical trial, greater mortality and decreased efficacy were reported in tigecycline-treated patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="_753ed7ff-ca5a-082d-2562-97499426787c">
                     <id root="6db03e71-85cf-c415-001c-6bf017e54440"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>1.5 Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of tigecycline for injection and other antibacterial drugs, tigecycline for injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. </paragraph>
                        <paragraph>Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to tigecycline. Tigecycline for injection may be initiated as empiric monotherapy before results of these tests are known. </paragraph>
                     </text>
                     <effectiveTime value="20170220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="77231048-bd5f-f859-e0c0-ad64209c2b97"/>
               <code code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Initial dose of 100 mg, followed by 50 mg every 12 hours administered intravenously over approximately 30 to 60 minutes. (2.1)</paragraph>
                        <list>
                           <item>Severe hepatic impairment (Child Pugh C): Initial dose of 100 mg followed by 25 mg every 12 hours. (<linkHtml href="#s19">2.2</linkHtml>)</item>
                           <item>Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with tigecyclineetracycline. (<linkHtml href="#_9a5a4fae-0096-494c-fb5c-250bd2e7c2e1">2.4</linkHtml>, <linkHtml href="#s9">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s8">
                     <id root="9812264d-ea28-1cbd-8940-5b406872683f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.1 Recommended Adult Dosage</title>
                     <text>
                        <paragraph>The recommended dosage regimen for tigecycline for injection is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous infusions of tigecycline for injection should be administered over approximately 30 to 60 minutes every 12 hours. </paragraph>
                        <paragraph>The recommended duration of treatment with tigecycline for injection for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days. The recommended duration of treatment with tigecycline for injection for community-acquired bacterial pneumonia is 7 to 14 days. The duration of therapy should be guided by the severity and site of the infection and the patient's clinical and bacteriological progress. </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="s9">
                     <id root="7e0359be-955c-b494-7cd7-93cfdcb2719a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.2 Dosage in Patients With Hepatic Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B). In patients with severe hepatic impairment (Child Pugh C), the initial dose of tigecycline for injection should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours. Patients with severe hepatic impairment (Child Pugh C) should be treated with caution and monitored for treatment response <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s43">12.3</linkHtml>) and Use in Specific Populations (<linkHtml href="#s38">8.6</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="61cbf949-73d6-4395-6598-7ee9e55de2ab"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.3 Dosage in Pediatric Patients</title>
                     <text>
                        <paragraph>The safety and efficacy of the proposed pediatric dosing regimens have not been evaluated due to the observed increase in mortality associated with tigecycline for injection in adult patients. Avoid use of tigecycline for injection in pediatric patients unless no alternative antibacterial drugs are available. Under these circumstances, the following doses are suggested:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Pediatric patients aged 8 to 11 years should receive 1.2 mg/kg of tigecycline for injection every 12 hours intravenously to a maximum dose of 50 mg of tigecycline for injection every 12 hours.</item>
                           <item>Pediatric patients aged 12 to 17 years should receive 50 mg of tigecycline for injection every 12 hours.</item>
                        </list>
                        <paragraph>The proposed pediatric doses of tigecycline for injection were chosen based on exposures observed in pharmacokinetic trials, which included small numbers of pediatric patients <content styleCode="italics">[see<linkHtml href="#S8.4"> Use in Specific Populations (8.4) </linkHtml>and<linkHtml href="#S12.3"> Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>There are no data to provide dosing recommendations in pediatric patients with hepatic impairment.</paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="_9a5a4fae-0096-494c-fb5c-250bd2e7c2e1">
                     <id root="f2fa14ad-21a5-36ea-4bb9-c0fb59839c20"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.4 Monitoring of Blood Coagulation Parameters</title>
                     <text>
                        <paragraph>Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with tigecycline for injection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.6</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="_b107569a-31d5-1f1b-c02b-b1ac4e102087">
                     <id root="6b5575e1-9132-d815-ad1f-1264150ecdd5"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>2.5 Preparation and Administration<content styleCode="bold"> </content>
                     </title>
                     <text>
                        <paragraph> Each vial of tigecycline for injection should be reconstituted with 5.3 mL of 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, or Lactated Ringer’s Injection, USP to achieve a concentration of 10 mg/mL of tigecycline. (Note: Each vial contains a 6% overage. Thus, 5 mL of reconstituted solution is equivalent to 50 mg of the drug.) The vial should be gently swirled until the drug dissolves. Reconstituted solution must be transferred and further diluted for intravenous infusion. Withdraw 5 mL of the reconstituted solution from the vial and add to a 100 mL intravenous bag for infusion (for a 100 mg dose, reconstitute two vials; for a 50 mg dose, reconstitute one vial). The maximum concentration in the intravenous bag should be 1 mg/mL. <content styleCode="underline">The reconstituted solution should be yellow to orange in color; if not, the solution should be discarded.</content> Parenteral drug products should be inspected visually for particulate matter and discoloration (e.g., green or black) prior to administration. Once reconstituted, tigecycline for injection may be stored at room temperature (not to exceed 25ºC/77ºF) for up to 24 hours (up to 6 hours in the vial and the remaining time in the intravenous bag). If the storage conditions exceed 25ºC (77ºF) after reconstitution, tigecycline should be used immediately. Alternatively, tigecycline for injection mixed with 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP may be stored refrigerated at 2° to 8°C (36° to 46°F) for up to 48 hours following immediate transfer of the reconstituted solution into the intravenous bag.</paragraph>
                        <paragraph>Tigecycline for injection may be administered intravenously through a dedicated line or through a Y-site. If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of tigecycline for injection with 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP or Lactated Ringer’s Injection, USP. Injection should be made with an infusion solution compatible with tigecycline and with any other drug(s) administered via this common line. </paragraph>
                     </text>
                     <effectiveTime value="20200728"/>
                  </section>
               </component>
               <component>
                  <section ID="_6caa9d54-3237-da2d-77f1-e34a613290f6">
                     <id root="6df8851a-f4b5-f27b-4d5a-9055cf0af00b"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content styleCode="none">2.6 Drug Compatibilities </content>
                     </title>
                     <text>
                        <paragraph>Compatible intravenous solutions include 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, and Lactated Ringer’s Injection, USP. When administered through a Y-site, tigecycline for injection is compatible with the following drugs or diluents when used with either 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer’s, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin. </paragraph>
                     </text>
                     <effectiveTime value="20200728"/>
                  </section>
               </component>
               <component>
                  <section ID="_2e26a20f-f62c-3298-d3ea-c1bad18cd3f7">
                     <id root="ab593373-d43e-8444-86f5-064eb26c8f2d"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content styleCode="none">2.7 Drug Incompatibilities </content>
                     </title>
                     <text>
                        <paragraph>The following drugs should not be administered simultaneously through the same Y-site as tigecycline for injection: amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, and omeprazole. </paragraph>
                     </text>
                     <effectiveTime value="20200728"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="G846d5da0-6288-4d84-be0e-f0a5920faccb">
               <id root="4828ac5d-6350-568a-f438-010d0fa95ec6"/>
               <code code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>For Injection: Each single-dose 5 mL glass vial contains 50 mg of tigecycline, USP as an orange lyophilized powder for reconstitution. </paragraph>
               </text>
               <effectiveTime value="20100730"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For Injection: 50 mg, lyophilized powder for reconstitution in a single-dose 5 mL vial. (<linkHtml href="#s13">3</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="9d0dab55-065d-48d1-d46f-726a978c474b"/>
               <code code="34070-3" displayName="CONTRAINDICATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange"/>Tigecycline for injection is contraindicated for use in patients who have known hypersensitivity to tigecycline or to any of the excipients. Reactions have included anaphylactic reactions <content styleCode="italics">[</content>
                     <content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s17">5.3</linkHtml>) and Adverse Reactions (<linkHtml href="#_3476aa79-3a10-ab0d-8b26-063a5fae66c6">6.2</linkHtml>)</content>
                     <content styleCode="italics">]</content>.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Known hypersensitivity to tigecycline. (<linkHtml href="#s14">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s15">
               <id root="ce4e14f8-46c9-b151-e49d-ebdc4cffd6fc"/>
               <code code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>
                              <content styleCode="underline">All-Cause Mortality:</content> A meta-analysis of Phase 3 and 4 clinical trials demonstrated an increase in all-cause mortality in tigecycline-treated patients compared to controls with a risk difference of 0.6% (95% CI 0.1, 1.2). The cause of this increase has not been established. An increase was also seen in a meta-analysis limited to the approved indications [0.6% (95% CI 0, 1.2)]. The greatest difference in mortality was seen in tigecycline-treated patients with ventilator-associated pneumonia. (<linkHtml href="#G48e27390-2b2a-4912-bd7a-d357ad7ec0d3">5.1</linkHtml>, <linkHtml href="#s16">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Anaphylactic Reactions:</content> have been reported with tigecycline for injection and may be life-threatening. Avoid use in patients with known hypersensitivity to tetracyclines. (<linkHtml href="#s17">5.3</linkHtml>) </item>
                           <item>
                              <content styleCode="underline">Hepatic Adverse Effects:</content> have been reported with tigecycline for injection. Patients who develop abnormal liver function tests during tigecycline for injection therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. (<linkHtml href="#s18">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Pancreatitis:</content> including fatalities, has been reported with tigecycline for injection. If pancreatitis is suspected, then consider stopping tigecycline for injection. (<linkHtml href="#G97ee3a67-817a-472d-b952-b0579694b286">5.5</linkHtml>) </item>
                           <item>
                              <content styleCode="underline"> Monitoring Blood Coagulation Parameters:</content> Hypofibrinogenemia has been reported with tigecycline for injection. Monitor blood coagulation parameters, including fibrinogen, at baseline and regularly during treatment with tigecycline for injection. (<linkHtml href="#s19">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Tooth Discoloration and Enamel Hypoplasia:</content> The use of tigecycline for injection during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia. (<linkHtml href="#s20">5.7</linkHtml>) </item>
                           <item>
                              <content styleCode="underline">Inhibition of Bone Growth:</content> The use of tigecycline for injection during the second and third trimester of pregnancy, infancy, and childhood up to the age of 8 years may cause reversible inhibition of bone growth. (<linkHtml href="#s21">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="italics underline">Clostridioides difficile </content>
                              <content styleCode="underline">associated Diarrhea (CDAD):</content> evaluate if diarrhea occurs. <linkHtml href="#s22">(5.9</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_d7bcb6ac-c57a-2238-d878-73fbf33da1ea">
                     <id root="1a5c7d43-7d2d-dac9-3ced-b95069a89647"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.1 All-Cause Mortality </title>
                     <text>
                        <paragraph>An increase in all-cause mortality has been observed in a meta-analysis of Phase 3 and 4 clinical trials in tigecycline-treated patients versus comparator-treated patients. In all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4% (150/3,788) of patients receiving tigecycline for injection and 3% (110/3,646) of patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, the adjusted risk difference of all-cause mortality was 0.6% (95% CI 0.1, 1.2) between tigecycline for injection and comparator-treated patients. An analysis of mortality in all trials conducted for approved indications (cSSSI, cIAI, and CABP), including post-market trials showed an adjusted mortality rate of 2.5% (66/2,640) for tigecycline and 1.8% (48/2,628) for comparator, respectively. The adjusted risk difference for mortality stratified by trial weight was 0.6% (95% CI 0, 1.2). </paragraph>
                        <paragraph>The cause of this mortality difference has not been established. Generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities. Tigecycline for injection should be reserved for use in situations when alternative treatments are not suitable <content styleCode="italics">[see Boxed Warning, Indications and Usage (<linkHtml href="#s6">1.4</linkHtml>), Warnings and Precautions (<linkHtml href="#s16">5.2</linkHtml>) and Adverse Reactions (<linkHtml href="#Gd3838ed3-f815-4394-b56c-5712b13e6a41">6.1</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="5881ae4e-799c-3b50-fc83-50c4eb476fe5"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.2 Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia</title>
                     <text>
                        <paragraph>A trial of patients with hospital acquired, including ventilator-associated, pneumonia failed to demonstrate the efficacy of tigecycline for injection. In this trial, patients were randomized to receive tigecycline for injection (100 mg initially, then 50 mg every 12 hours) or a comparator. In addition, patients were allowed to receive specified adjunctive therapies. The sub-group of patients with ventilator-associated pneumonia who received tigecycline for injection had lower cure rates (47.9% versus 70.1% for the clinically evaluable population). </paragraph>
                        <paragraph>In this trial, greater mortality was seen in patients with ventilator-associated pneumonia who received tigecycline for injection (25/131 [19.1%] versus 15/122 [12.3%] in comparator-treated patients) <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Gd3838ed3-f815-4394-b56c-5712b13e6a41">6.1</linkHtml>)]</content>. Particularly high mortality was seen among tigecycline-treated patients with ventilator-associated pneumonia and bacteremia at baseline (9/18 [50%] versus 1/13 [7.7%] in comparator-treated patients). </paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="901cfb73-6983-f92f-47a4-99c105e03c71"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.3 Anaphylactic Reactions </title>
                     <text>
                        <paragraph>Anaphylactic reactions have been reported with nearly all antibacterial agents, including tigecycline for injection, and may be life-threatening. Tigecycline for injection is structurally similar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs. </paragraph>
                     </text>
                     <effectiveTime value="20200728"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="7aa76326-9b9d-4f8f-c681-dbe9e1045194"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.4 Hepatic Adverse Effects </title>
                     <text>
                        <paragraph>Increases in total bilirubin concentration, prothrombin time and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications. Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. Hepatic dysfunction may occur after the drug has been discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20130329"/>
                  </section>
               </component>
               <component>
                  <section ID="G97ee3a67-817a-472d-b952-b0579694b286">
                     <id root="9c99ba1b-9431-8f92-5ff4-427d620e4a90"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.5 Pancreatitis</title>
                     <text>
                        <paragraph>Acute pancreatitis, including fatal cases, has occurred in association with tigecycline treatment. The diagnosis of acute pancreatitis should be considered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis. Cases have been reported in patients without known risk factors for pancreatitis. Patients usually improve after tigecycline discontinuation. Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having developed pancreatitis <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#s28">6.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20130329"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="852274a9-523e-49d3-510a-e455c2c6af46"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content styleCode="bold">5.6 Monitoring of Blood Coagulation Parameters</content>
                     </title>
                     <text>
                        <paragraph>Hypofibrinogenemia has been reported in patients treated with tigecycline for injection <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#_3476aa79-3a10-ab0d-8b26-063a5fae66c6">6.2</linkHtml>)]</content>. Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with tigecycline for injection.  </paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="s20">
                     <id root="e4ccc1fd-c71a-5790-80e4-84f12fe7774f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.7 Tooth Discoloration and Enamel Hypoplasia</title>
                     <text>
                        <paragraph> The use of tigecycline for injection during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of tetracyclines, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Advise the patient of the potential risk to the fetus if tigecycline for injection is used during the second or third trimester of pregnancy <content styleCode="italics">[see Use in Specific Populations (8.1, <linkHtml href="#s36"> 8.4</linkHtml>)].  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="_2aa1a282-375c-f088-8914-128f71f31bfa">
                     <id root="a4996d13-a001-f87a-392c-d4195138e994"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content styleCode="bold">5.8 Inhibition of Bone Growth</content>
                     </title>
                     <text>
                        <paragraph>The use of tigecycline for injection during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the tetracycline was discontinued. Advise the patient of the potential risk to the fetus if tigecycline for injection is used during the second or third trimester of pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s33">8.1</linkHtml>, 8.4)]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="26451910-32b6-aed7-8ab0-361507c6c15f"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.9 <content styleCode="italics">Clostridioides difficile</content> Associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including tigecycline for injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>. </paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated. </paragraph>
                     </text>
                     <effectiveTime value="20210331"/>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="67754350-06f1-e222-c9ab-dd73340197eb"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.10 Sepsis/Septic Shock in Patients With Intestinal Perforation</title>
                     <text>
                        <paragraph> Monotherapy with tigecycline should be avoided in patients with complicated intra-abdominal infections (cIAI) secondary to clinically apparent intestinal perforation. In cIAI studies (n=1,642), 6 patients treated with tigecycline for injection and 2 patients treated with imipenem/cilastatin presented with intestinal perforations and developed sepsis/septic shock. The 6 patients treated with tigecycline for injection had higher APACHE II scores (median = 13) versus the 2 patients treated with imipenem/cilastatin (APACHE II scores = 4 and 6). Due to differences in baseline APACHE II scores between treatment groups and small overall numbers, the relationship of this outcome to treatment cannot be established. </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="fdae1683-bc13-4cfc-2693-c795ff7ac891"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.11 Tetracycline-Class Adverse Effects</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Tigecycline for injection is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse effects. Such effects may include: photosensitivity, fixed drug eruption, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, and hyperphosphatemia). Discontinue tigecycline for injection if any of these adverse reactions are suspected.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="ed7c7791-cbed-8d01-131c-d917cf463304"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>5.12 Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing tigecycline for injection in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. </paragraph>
                     </text>
                     <effectiveTime value="20200728"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="G8ecdd4ec-efba-4dd0-8878-894ac13bf2d7">
               <id root="3f4d2a9f-faa0-0f87-5f25-94af28c02650"/>
               <code code="34084-4" displayName="ADVERSE REACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling: </paragraph>
                  <list>
                     <item>
                        <paragraph>All-Cause Mortality <content styleCode="italics">[see Boxed Warning and Warnings and Precautions (<linkHtml href="#_d7bcb6ac-c57a-2238-d878-73fbf33da1ea">5.1</linkHtml>)] </content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.2</linkHtml>)]</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>Anaphylaxis <content styleCode="italics">[Warning and Precautions (<linkHtml href="#s17">5.3</linkHtml>)] </content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>Hepatic Adverse Effects <content styleCode="italics">[Warnings and Precautions (<linkHtml href="#s18">5.4</linkHtml>)]</content>
                        </paragraph>
                     </item>
                     <item>
                        <paragraph>Pancreatitis <content styleCode="italics">[Warnings and Precautions (<linkHtml href="#G97ee3a67-817a-472d-b952-b0579694b286">5.5</linkHtml>)]</content>
                        </paragraph>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20200728"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (incidence &gt;5%) are nausea, <content styleCode="none"> </content>vomiting, diarrhea, abdominal pain, headache, and increased SGPT. (<linkHtml href="#s27">6.1</linkHtml>) </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Apotex at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Gd3838ed3-f815-4394-b56c-5712b13e6a41">
                     <id root="d7e1eab6-5429-9e96-ee38-297f79b44082"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>
                           <content styleCode="none"/>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>In clinical trials, 2,514 patients were treated with tigecycline for injection. Tigecycline for injection was discontinued due to adverse reactions in 7% of patients compared to 6% for all comparators. <linkHtml href="#t1">Table 1</linkHtml> shows the incidence of adverse reactions through test of cure reported in ≥2% of patients in these trials. </paragraph>
                        <table ID="t1" width="100%">
                           <caption ID="G543c8624-2d9a-4991-aa38-670fcecc7eac">Table 1. Incidence (%) of Adverse Reactions Through Test of Cure Reported in ≥ 2% of Patients Treated in Clinical Studies </caption>
                           <colgroup>
                              <col align="left" width="50%"/>
                              <col align="center" width="25%"/>
                              <col align="center" width="25%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th>
                                    <content styleCode="bold">Body System </content>
                                 </th>
                                 <th>Tigecycline for injection</th>
                                 <th>Comparators<sup>a </sup>
                                 </th>
                              </tr>
                              <tr>
                                 <td>Adverse Reactions</td>
                                 <td>(N=2,514)</td>
                                 <td>(N=2,307)</td>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> Vancomycin/Aztreonam, Imipenem/Cilastatin, Levofloxacin, Linezolid.<paragraph>
                                       <sup>b</sup> LFT abnormalities in tigecycline-treated patients were reported more frequently in the post therapy period than those in comparator-treated patients, which occurred more often on therapy. </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Body as a Whole</content>
                                 </td>
                                 <td align="center"> </td>
                                 <td> </td>
                              </tr>
                              <tr>
                                 <td>   Abdominal pain </td>
                                 <td align="center">6 </td>
                                 <td align="center">4 </td>
                              </tr>
                              <tr>
                                 <td>   Abscess </td>
                                 <td align="center">2 </td>
                                 <td align="center">2 </td>
                              </tr>
                              <tr>
                                 <td>   Asthenia </td>
                                 <td align="center">3 </td>
                                 <td align="center">2 </td>
                              </tr>
                              <tr>
                                 <td>   Headache </td>
                                 <td align="center">6 </td>
                                 <td align="center">7 </td>
                              </tr>
                              <tr>
                                 <td>   Infection </td>
                                 <td align="center">7 </td>
                                 <td align="center">5 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Cardiovascular System</content>
                                 </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td>   Phlebitis </td>
                                 <td align="center">3 </td>
                                 <td align="center">4 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Digestive System</content>
                                 </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td>   Diarrhea </td>
                                 <td align="center">12 </td>
                                 <td align="center">11 </td>
                              </tr>
                              <tr>
                                 <td>   Dyspepsia </td>
                                 <td align="center">2 </td>
                                 <td align="center" valign="middle">2 </td>
                              </tr>
                              <tr>
                                 <td>   Nausea </td>
                                 <td align="center">26 </td>
                                 <td align="center">13 </td>
                              </tr>
                              <tr>
                                 <td>   Vomiting </td>
                                 <td align="center">18 </td>
                                 <td align="center">9 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Hemic and Lymphatic System</content>
                                 </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td>   Anemia </td>
                                 <td align="center">5 </td>
                                 <td align="center">6 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Metabolic and Nutritional</content>
                                 </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td>   Alkaline Phosphatase <br/>   Increased </td>
                                 <td align="center">3 </td>
                                 <td align="center">3 </td>
                              </tr>
                              <tr>
                                 <td>   Amylase Increased </td>
                                 <td align="center">3 </td>
                                 <td align="center">2 </td>
                              </tr>
                              <tr>
                                 <td>   Bilirubinemia </td>
                                 <td align="center">2 </td>
                                 <td align="center">1 </td>
                              </tr>
                              <tr>
                                 <td>   BUN Increased </td>
                                 <td align="center">3 </td>
                                 <td align="center">1 </td>
                              </tr>
                              <tr>
                                 <td>   Healing Abnormal </td>
                                 <td align="center">3 </td>
                                 <td align="center">2 </td>
                              </tr>
                              <tr>
                                 <td>   Hyponatremia </td>
                                 <td align="center">2</td>
                                 <td align="center">1</td>
                              </tr>
                              <tr>
                                 <td>   Hypoproteinemia </td>
                                 <td align="center">5 </td>
                                 <td align="center">3 </td>
                              </tr>
                              <tr>
                                 <td>   SGOT Increased<sup>b</sup>
                                 </td>
                                 <td align="center">4 </td>
                                 <td align="center">5 </td>
                              </tr>
                              <tr>
                                 <td>   SGPT Increased<sup>b</sup>
                                 </td>
                                 <td align="center">5 </td>
                                 <td align="center">5 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Respiratory System</content>
                                 </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td>   Pneumonia</td>
                                 <td align="center">2 </td>
                                 <td align="center">2 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Nervous System</content>
                                 </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td>   Dizziness </td>
                                 <td align="center">3 </td>
                                 <td align="center" valign="middle">3 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Skin and Appendages</content>
                                 </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td styleCode="BOTRULE">   Rash </td>
                                 <td align="center" styleCode="BOTRULE">3 </td>
                                 <td align="center" styleCode="BOTRULE">4 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In all 13 Phase 3 and 4 trials that included a comparator, death occurred in 4% (150/3,788) of patients receiving tigecycline for injection and 3% (110/3,646) of patients receiving comparator drugs. In a pooled analysis of these trials, based on a random effects model by trial weight, an adjusted risk difference of all-cause mortality was 0.6% (95% CI 0.1, 1.2) between tigecycline for injection and comparator-treated patients (see Table 2). The cause of the imbalance has not been established. Generally, deaths were the result of worsening infection, complications of infection or underlying co-morbidities.</paragraph>
                        <table ID="t2a" width="100%">
                           <caption ID="G562aa03e-5937-4875-ba8e-78c212d0b081">Table 2. Patients with Outcome of Death by Infection Type</caption>
                           <colgroup>
                              <col align="left" width="20%"/>
                              <col align="center" width="15%"/>
                              <col align="center" width="15%"/>
                              <col align="center" width="15%"/>
                              <col align="center" width="15%"/>
                              <col align="center" width="20%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th/>
                                 <th colspan="2">Tigecycline for injection</th>
                                 <th colspan="2">Comparator</th>
                                 <th>Risk Difference*</th>
                              </tr>
                              <tr>
                                 <th>
                                    <content styleCode="none">Infection Type</content>
                                 </th>
                                 <th>
                                    <content styleCode="none">n/N</content>
                                 </th>
                                 <th>%</th>
                                 <th>
                                    <content styleCode="none">n/N</content>
                                 </th>
                                 <th>%</th>
                                 <th>% (95% CI)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="6">CAP = Community-acquired pneumonia; cIAI = Complicated intra-abdominal infections; cSSSI = Complicated skin and skin structure infections; HAP = Hospital-acquired pneumonia; VAP = Ventilator-associated pneumonia; RP = Resistant pathogens; DFI = Diabetic foot infections.<paragraph>* The difference between the percentage of patients who died in tigecycline for injection and comparator treatment groups. The 95% CI for each infection type was calculated using the normal approximation method without continuity correction.</paragraph>
                                    <paragraph>** Overall adjusted (random effects model by trial weight) risk difference estimate and 95% CI.</paragraph>
                                    <paragraph>
                                       <sup>a</sup> These are subgroups of the HAP population. </paragraph>
                                    <paragraph>Note: The studies include 300, 305, 900 (cSSSI), 301, 306, 315, 316, 400 (cIAI), 308 and 313 (CAP), 311 (HAP), 307 [Resistant gram-positive pathogen study in patients with MRSA or Vancomycin-Resistant Enterococcus (VRE)], and 319 (DFI with and without osteomyelitis). </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td>cSSSI</td>
                                 <td align="center">12/834</td>
                                 <td align="center">1.4</td>
                                 <td align="center">6/813</td>
                                 <td align="center">0.7</td>
                                 <td align="center">0.7 (-0.3, 1.7)</td>
                              </tr>
                              <tr>
                                 <td>cIAI</td>
                                 <td align="center">42/1,382</td>
                                 <td align="center">3.0</td>
                                 <td align="center">31/1,393</td>
                                 <td align="center">2.2</td>
                                 <td align="center">0.8 (-0.4, 2.0)</td>
                              </tr>
                              <tr>
                                 <td>CAP</td>
                                 <td align="center">12/424</td>
                                 <td align="center">2.8</td>
                                 <td align="center">11/422</td>
                                 <td align="center">2.6</td>
                                 <td align="center">0.2 (-2.0, 2.4)</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td>HAP</td>
                                 <td align="center">66/467</td>
                                 <td align="center">14.1</td>
                                 <td align="center">57/467</td>
                                 <td align="center">12.2</td>
                                 <td align="center">1.9 (-2.4, 6.3)</td>
                              </tr>
                              <tr>
                                 <td>   Non-VAP<sup>a</sup>
                                 </td>
                                 <td align="center">41/336</td>
                                 <td align="center">12.2</td>
                                 <td align="center">42/345</td>
                                 <td align="center">12.2</td>
                                 <td align="center">0.0 (-4.9, 4.9)</td>
                              </tr>
                              <tr>
                                 <td>   VAP<sup>a</sup>
                                 </td>
                                 <td align="center">25/131</td>
                                 <td align="center">19.1</td>
                                 <td align="center">15/122</td>
                                 <td align="center">12.3</td>
                                 <td align="center">6.8 (-2.1, 15.7)</td>
                              </tr>
                              <tr>
                                 <td>RP</td>
                                 <td align="center">11/128</td>
                                 <td align="center">8.6</td>
                                 <td align="center">2/43</td>
                                 <td align="center">4.7</td>
                                 <td align="center">3.9 (-4.0, 11.9)</td>
                              </tr>
                              <tr>
                                 <td>DFI</td>
                                 <td align="center">7/553</td>
                                 <td align="center">1.3</td>
                                 <td align="center">3/508</td>
                                 <td align="center">0.6</td>
                                 <td align="center">0.7 (-0.5, 1.8)</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                                 <td align="center"> </td>
                              </tr>
                              <tr>
                                 <td>Overall Adjusted</td>
                                 <td align="center">150/3,788</td>
                                 <td align="center">4.0</td>
                                 <td align="center">110/3,646</td>
                                 <td align="center">3.0</td>
                                 <td align="center">0.6 (0.1, 1.2)**</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>An analysis of mortality in all trials conducted for approved indications -cSSSI, cIAI, and CABP, including post-market trials (one in cSSSI and two in cIAI) - showed an adjusted mortality rate of 2.5% (66/2,640) for tigecycline and 1.8% (48/2,628) for comparator, respectively. The adjusted risk difference for mortality stratified by trial weight was 0.6% (95% CI 0, 1.2). </paragraph>
                        <paragraph>In comparative clinical studies, infection-related serious adverse reactions were more frequently reported for subjects treated with tigecycline for injection (7%) versus comparators (6%). Serious adverse reactions of sepsis/septic shock were more frequently reported for subjects treated with tigecycline for injection (2%) versus comparators (1%). Due to baseline differences between treatment groups in this subset of patients, the relationship of this outcome to treatment cannot be established <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.10</linkHtml>)]. </content>
                        </paragraph>
                        <paragraph>The most common adverse reactions were nausea and vomiting which generally occurred during the first 1 to 2 days of therapy. The majority of cases of nausea and vomiting associated with tigecycline for injection and comparators were either mild or moderate in severity. In patients treated with tigecycline for injection, nausea incidence was 26% (17% mild, 8% moderate, 1% severe) and vomiting incidence was 18% (11% mild, 6% moderate, 1% severe). </paragraph>
                        <paragraph>In patients treated for complicated skin and skin structure infections (cSSSI), nausea incidence was 35% for tigecycline for injection and 9% for vancomycin/aztreonam; vomiting incidence was 20% for tigecycline for injection and 4% for vancomycin/aztreonam. In patients treated for complicated intra-abdominal infections (cIAI), nausea incidence was 25% for tigecycline for injection and 21% for imipenem/cilastatin; vomiting incidence was 20% for tigecycline for injection and 15% for imipenem/cilastatin. In patients treated for community-acquired bacterial pneumonia (CABP), nausea incidence was 24% for tigecycline for injection and 8% for levofloxacin; vomiting incidence was 16% for tigecycline for injection and 6% for levofloxacin. </paragraph>
                        <paragraph>Discontinuation from tigecycline for injection was most frequently associated with nausea (1%) and vomiting (1%). For comparators, discontinuation was most frequently associated with nausea (&lt;1%).  </paragraph>
                        <paragraph>The following adverse reactions were reported (&lt;2%) in patients receiving tigecycline for injection in clinical studies:  </paragraph>
                        <paragraph>
                           <content styleCode="italics">Body as a Whole</content>: injection site inflammation, injection site pain, injection site reaction, septic shock, allergic reaction, chills, injection site edema, injection site phlebitis </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular System:</content> thrombophlebitis </paragraph>
                        <paragraph>
                           <content styleCode="italics">Digestive System:</content> anorexia, jaundice, abnormal stools </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolic/Nutritional System:</content> increased creatinine, hypocalcemia, hypoglycemia </paragraph>
                        <paragraph>
                           <content styleCode="italics">Special Senses:</content> taste perversion </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hemic and Lymphatic System</content>: prolonged activated partial thromboplastin time (aPTT), prolonged prothrombin time (PT), eosinophilia, increased international normalized ratio (INR), thrombocytopenia </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Appendages:</content> pruritus </paragraph>
                        <paragraph>
                           <content styleCode="italics">Urogenital System:</content> vaginal moniliasis, vaginitis, leukorrhea </paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="_3476aa79-3a10-ab0d-8b26-063a5fae66c6">
                     <id root="0ed770ca-2ced-a6ac-195c-f0e71c85fba6"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>6.2 Post-Marketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of tigecycline for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure.</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>anaphylactic reactions</item>
                           <item>acute pancreatitis</item>
                           <item>hepatic cholestasis, and jaundice</item>
                           <item>severe skin reactions, including Stevens-Johnson Syndrome</item>
                           <item>symptomatic hypoglycemia in patients with and without diabetes mellitus</item>
                           <item>hypofibrinogenemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.6</linkHtml>)]</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s29">
               <id root="181ab161-adee-409e-3921-64e7b72c9b68"/>
               <code code="34073-7" displayName="DRUG INTERACTIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20200728"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list ID="Gb65bb431-2318-436d-a279-eb772c69d64a" listType="unordered" styleCode="Disc">
                           <item>Warfarin: Suitable anticoagulation test should be monitored if tigecycline for injection is administered to patients receiving warfarin. (<linkHtml href="#s30">7.1</linkHtml>)</item>
                           <item>Calcineurin Inhibitors: Serum concentrations of calcineurin inhibitors (e.g., tacrolimus, cyclosporine) should be monitored during treatment with tigecycline for injection due to risk of toxicity. (<linkHtml href="#s31">7.2</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s30">
                     <id root="6fdabffd-01c5-1bbd-4b6b-5dee612ebb89"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.1 Warfarin </title>
                     <text>
                        <paragraph>Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s43">12.3</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="_8811644d-afed-2267-30d5-a997e40c6879">
                     <id root="55ca8d62-afb1-aa70-c24b-0f472466d09a"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>
                        <content styleCode="bold">7.2 Calcineurin Inhibitors</content>
                     </title>
                     <text>
                        <paragraph>Concomitant use of tigecycline for injection and calcineurin inhibitors such as tacrolimus or cyclosporine may lead to an increase in serum trough concentrations of the calcineurin inhibitors. Therefore, serum concentrations of the calcineurin inhibitor should be monitored during treatment with tigecycline for injection to avoid drug toxicity. </paragraph>
                     </text>
                     <effectiveTime value="20200728"/>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="93b8e0c8-2e58-9dd7-8771-cc22e508b2eb"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>7.3 Oral Contraceptives </title>
                     <text>
                        <paragraph>Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective. </paragraph>
                     </text>
                     <effectiveTime value="20200728"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="G2d8d0da4-5cdf-450b-8fd8-de30642bd23a">
               <id root="e3aab5b8-9f7f-87e5-9798-889584eec017"/>
               <code code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20200728"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>
                              <content styleCode="underline">Lactation:</content> Avoid breastfeeding for longer than 3 weeks while taking tigecycline for injection. A lactating woman may also pump and discard breast milk during treatment and for 9 days after the last dose of tigecycline for injection (<linkHtml href="#_f8b8cb58-2984-8d4e-25ce-209e1c829a66">8.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Pediatrics:</content> Use in patients under 18 years of age is not recommended. Pediatric trials were not conducted because of the higher risk of mortality seen in adult trials (<linkHtml href="#s36">8.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s33">
                     <id root="48ee3ece-3afa-4537-7ad7-513324809bd0"/>
                     <code code="42228-7" displayName="PREGNANCY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Tigecycline for injection, like other tetracycline class antibacterial drugs, may cause permanent discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy <content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#s20">5.7</linkHtml>, 5.8), </content>
                           <content styleCode="italics">Data,</content> and <content styleCode="italics"> Use in Specific Populations (<linkHtml href="#s36">8.4</linkHtml>)]</content>. There are no available data on the risk of major birth defects or miscarriage following the use of tigecycline for injection during pregnancy. Administration of intravenous tigecycline in pregnant rats and rabbits during the period of organogenesis was associated with reduction in fetal weights and an increased incidence of skeletal anomalies (delays in bone ossification) at exposures of 5 and 1 times the human exposure at the recommended clinical dose in rats and rabbits, respectively. Advise the patient of the potential risk to the fetus if tigecycline for injection is used during the second or third trimester. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U. S. general population, the estimated background risk in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data </content>   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data </content>   </paragraph>
                        <paragraph>The use of tetracycline-class antibacterial drugs, that includes tigecycline for injection, during tooth development (second and third trimester of pregnancy) may cause permanent discoloration of deciduous teeth. This adverse reaction is more common during long-term use of tetracyclines but has been observed following repeated short-term courses. Tigecycline for injection may cause reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy. A decrease in fibula growth rate has been observed in premature infants given oral tetracycline in doses of 25 mg/kg every 6 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data </content>   </paragraph>
                        <paragraph> In embryo-fetal development studies, tigecycline was administered during the period of organogenesis at doses up to 12 mg/kg/day in rats and 4 mg/kg in rabbits or 5 and 1 times the systemic exposure at the recommended clinical dose, respectively. In the rat study, decreased fetal weight and fetal skeletal variations (reduced ossification of the pubic, ischial, and supraoccipital bones and increased incidences of rudimentary 14<sup>th</sup> rib) were observed in the presence of maternal toxicity at 12 mg/kg/day (5 times the recommended clinical dose based on systemic exposure). In rabbits, decreased fetal weights were observed in the presence of maternal toxicity at 4 mg/kg (equivalent to the human exposure at the recommended clinical dose).   </paragraph>
                        <paragraph>In preclinical safety studies, <sup>14</sup>C-labeled tigecycline crossed the placenta and was found in fetal tissues.</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="_f8b8cb58-2984-8d4e-25ce-209e1c829a66">
                     <id root="92f106eb-46a0-25b1-6239-89a973141457"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>    </paragraph>
                        <paragraph> There are no data on the presence of tigecycline in human milk; however, tetracycline-class antibacterial drugs are present in breast milk. It is not known whether tigecycline has an effect on the breastfed infant or on milk production. Tigecycline has low oral bioavailability; therefore, infant exposure is expected to be low. Tigecycline is present in rat milk with little or no systemic exposure to tigecycline in nursing pups as a result of exposure via maternal milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk.    </paragraph>
                        <paragraph> The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for tigecycline for injection and any potential adverse effects on the breastfed child from tigecycline for injection or from the underlying maternal condition (see Clinical Considerations).     </paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations </content>   </paragraph>
                        <paragraph> Because of the theoretical risk of dental discoloration and inhibition of bone growth, avoid breastfeeding if taking tigecycline for injection for longer than three weeks. A lactating woman may also consider interrupting breastfeeding and pumping and discarding breastmilk during administration of tigecycline for injection and for 9 days (approximately 5 half-lives) after the last dose in order to minimize drug exposure to a breastfed infant.</paragraph>
                     </text>
                     <effectiveTime value="20200728"/>
                  </section>
               </component>
               <component>
                  <section ID="s36">
                     <id root="ba77f17a-6a3f-49dc-4eb1-8797481d0139"/>
                     <code code="34081-0" displayName="PEDIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Use in patients under 18 years of age is not recommended. Safety and effectiveness in pediatric patients below the age of 18 years have not been established. Because of the increased mortality observed in tigecycline-treated adult patients in clinical trials, pediatric trials of tigecycline to evaluate the safety and efficacy of tigecycline were not conducted. </paragraph>
                        <paragraph>In situations where there are no other alternative antibacterial drugs, dosing has been proposed for pediatric patients 8 to 17 years of age based on data from pediatric pharmacokinetic studies <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#S2.3">2.3</linkHtml>) and Clinical Pharmacology (<linkHtml href="#G2744aefe-8cc2-4281-be24-9be9ab1f978f">12.3</linkHtml>)]. </content>
                        </paragraph>
                        <paragraph>Because of effects on tooth development, use in patients under 8 years of age is not recommended <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s20">5.7</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="s37">
                     <id root="ee783bf7-2347-02f7-99bd-0ef9181fc6b3"/>
                     <code code="34082-8" displayName="GERIATRIC USE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the total number of subjects who received tigecycline for injection in Phase 3 clinical studies (n=2,514), 664 were 65 and over, while 288 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity to adverse events of some older individuals cannot be ruled out. </paragraph>
                        <paragraph>No significant difference in tigecycline exposure was observed between healthy elderly subjects and younger subjects following a single 100 mg dose of tigecycline <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s43">12.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="s38">
                     <id root="cba61178-179c-8858-0279-b01dc7eea9e8"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>8.6 Hepatic Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child Pugh A and Child Pugh B). In patients with severe hepatic impairment (Child Pugh C), the initial dose of tigecycline should be 100 mg followed by a reduced maintenance dose of 25 mg every 12 hours. Patients with severe hepatic impairment (Child Pugh C) should be treated with caution and monitored for treatment response <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s43">12.3</linkHtml>) and Dosage and Administration (<linkHtml href="#s9">2.2</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s39">
               <id root="4588ac3e-ee69-e7a8-44d6-2ae5df0bd826"/>
               <code code="34088-5" displayName="OVERDOSAGE SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>No specific information is available on the treatment of overdosage with tigecycline. Intravenous administration of tigecycline for injection at a single dose of 300 mg over 60 minutes in healthy volunteers resulted in an increased incidence of nausea and vomiting. Tigecycline is not removed in significant quantities by hemodialysis. </paragraph>
               </text>
               <effectiveTime value="20100730"/>
            </section>
         </component>
         <component>
            <section ID="G83fda7ea-7622-4701-a410-f57f76645c4f">
               <id root="1fbf6aba-7aaf-a200-7e88-a5da8403ed01"/>
               <code code="34089-3" displayName="DESCRIPTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Tigecycline, USP is a tetracycline class antibacterial for intravenous infusion. The chemical name of tigecycline is (4<content styleCode="italics">S</content>,4a<content styleCode="italics">S</content>,5a<content styleCode="italics">R</content>,12a<content styleCode="italics">S</content>)- 9-[2-(<content styleCode="italics">tert</content>-butylamino)acetamido]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2 naphthacenecarboxamide. The molecular formula is C<sub>29</sub>H<sub>39</sub>N<sub>5</sub>O<sub>8</sub> and the molecular weight is 585.65. </paragraph>
                  <paragraph>The following represents the chemical structure of tigecycline: </paragraph>
                  <content styleCode="none">
                     <renderMultiMedia referencedObject="Gefa1a97f-c6ec-4fd7-9993-b4f2bb87500d"/>
                  </content>
                  <paragraph>Figure 1: Structure of Tigecycline</paragraph>
                  <paragraph>Tigecycline for injection, USP is an orange lyophilized powder or cake. Each tigecycline for injection single-dose 5 mL vial contains 50 mg tigecycline, USP lyophilized powder for reconstitution for intravenous infusion and 100 mg of lactose monohydrate. The pH is adjusted with hydrochloric acid, and if necessary sodium hydroxide. The product does not contain preservatives. </paragraph>
               </text>
               <effectiveTime value="20250505"/>
               <component>
                  <observationMedia ID="Gefa1a97f-c6ec-4fd7-9993-b4f2bb87500d">
                     <text>chemical structure.jpg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="chemical structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s41">
               <id root="7e0b3033-d112-fac6-ae43-785ec5865dd0"/>
               <code code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20200728"/>
               <component>
                  <section ID="s42">
                     <id root="5e0e15e8-4d14-99d1-d014-1f97aa6ef4f0"/>
                     <code code="43679-0" displayName="MECHANISM OF ACTION SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Tigecycline is a tetracycline class antibacterial <content styleCode="italics">[see Microbiology (<linkHtml href="#s54">12.4</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="_3f9f1f8c-9d89-a7ee-71e6-738bacb2205d">
                     <id root="c843e96f-336c-6e47-8421-0c5515717d6e"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold italics">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>No significant effect of a single intravenous dose of tigecycline for injection 50 mg or 200 mg on QTc interval was detected in a randomized, placebo-and active-controlled four-arm crossover thorough QTc study of 46 healthy subjects.</paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="G2744aefe-8cc2-4281-be24-9be9ab1f978f">
                     <id root="434af664-c242-3cbb-0c8a-d0394c8b9eff"/>
                     <code code="43682-4" displayName="PHARMACOKINETICS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>The mean pharmacokinetic parameters of tigecycline after single and multiple intravenous doses based on pooled data from clinical pharmacology studies are summarized in <linkHtml href="#t2">Table 3</linkHtml>. Intravenous infusions of tigecycline were administered over approximately 30 to 60 minutes. </paragraph>
                        <table ID="t2" width="100%">
                           <caption ID="Gc597dfc0-ee67-4816-8fa5-ac6320d486a1">Table 3. Mean (CV%) Pharmacokinetic Parameters of Tigecycline </caption>
                           <colgroup>
                              <col align="left" width="40%"/>
                              <col align="center" width="30%"/>
                              <col align="center" width="30%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th> </th>
                                 <th>Single Dose </th>
                                 <th>Multiple Dose<sup>a</sup>
                                 </th>
                              </tr>
                              <tr>
                                 <th> </th>
                                 <th>100 mg</th>
                                 <th>50 mg every 12h</th>
                              </tr>
                              <tr>
                                 <th> </th>
                                 <th>(N=224)</th>
                                 <th>(N=103)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> 100 mg initially, followed by 50 mg every 12 hours<paragraph>
                                       <sup>b</sup> 30-minute infusion </paragraph>
                                    <paragraph>
                                       <sup>c</sup> 60-minute infusion </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>C<sub>max</sub> (mcg/mL)<sup>b</sup>
                                 </td>
                                 <td align="center" valign="middle">1.45 (22%) </td>
                                 <td align="center" valign="middle">0.87 (27%) </td>
                              </tr>
                              <tr>
                                 <td>C<sub>max</sub> (mcg/mL)<sup>c</sup>
                                 </td>
                                 <td align="center" valign="middle">0.90 (30%) </td>
                                 <td align="center" valign="middle">0.63 (15%) </td>
                              </tr>
                              <tr>
                                 <td>AUC (mcg·h/mL) </td>
                                 <td align="center" valign="middle">5.19 (36%) </td>
                                 <td align="center" valign="middle">- - </td>
                              </tr>
                              <tr>
                                 <td>AUC<sub>0-24h</sub> (mcg·h/mL) </td>
                                 <td align="center" valign="middle">- - </td>
                                 <td align="center" valign="middle">4.70 (36%) </td>
                              </tr>
                              <tr>
                                 <td>C<sub>min</sub> (mcg/mL) </td>
                                 <td align="center" valign="middle">- - </td>
                                 <td align="center" valign="middle">0.13 (59%) </td>
                              </tr>
                              <tr>
                                 <td>t<sub>½</sub> (h) </td>
                                 <td align="center" valign="middle">27.1 (53%) </td>
                                 <td align="center" valign="middle">42.4 (83%) </td>
                              </tr>
                              <tr>
                                 <td>CL (L/h) </td>
                                 <td align="center" valign="middle">21.8 (40%) </td>
                                 <td align="center" valign="middle">23.8 (33%) </td>
                              </tr>
                              <tr>
                                 <td>CL<sub>r</sub> (mL/min) </td>
                                 <td align="center" valign="middle">38.0 (82%) </td>
                                 <td align="center" valign="middle">51.0 (58%) </td>
                              </tr>
                              <tr>
                                 <td styleCode="BOTRULE">V<sub>ss</sub> (L) </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">568 (43%) </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">639 (48%) </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20200728"/>
                     <component>
                        <section ID="s44">
                           <id root="c14657a4-025b-bcd2-767a-f886f318ffce"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline"> Distribution</content>
                           </title>
                           <text>
                              <paragraph>The <content styleCode="italics">in vitro</content> plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1 mcg/mL). The steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/kg), indicating tigecycline is extensively distributed beyond the plasma volume and into the tissues. </paragraph>
                              <paragraph>Following the administration of tigecycline 100 mg followed by 50 mg every 12 hours to 33 healthy volunteers, the tigecycline AUC<sub>0-12h</sub> (134 mcg·h/mL) in alveolar cells was approximately 78-fold higher than the AUC<sub>0-12h</sub> in the serum, and the AUC<sub>0-12h</sub> (2.28 mcg·h/mL) in epithelial lining fluid was approximately 32% higher than the AUC<sub>0-12h</sub> in serum. The AUC<sub>0-12h</sub> (1.61 mcg·h/mL) of tigecycline in skin blister fluid was approximately 26% lower than the AUC<sub>0-12h</sub> in the serum of 10 healthy subjects. </paragraph>
                              <paragraph>In a single-dose study, tigecycline 100 mg was administered to subjects prior to undergoing elective surgery or medical procedure for tissue extraction. Concentrations at 4 hours after tigecycline administration were higher in gallbladder (38-fold, n=6), lung (3.7-fold, n=5), and colon (2.3-fold, n=6), and lower in synovial fluid (0.58-fold, n=5), and bone (0.35-fold, n=6) relative to serum. The concentration of tigecycline in these tissues after multiple doses has not been studied. </paragraph>
                           </text>
                           <effectiveTime value="20250505"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s45">
                           <id root="9f355d1a-def5-b8f0-7632-898bb8726c56"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Elimination</content>
                              <content styleCode="bold"/>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Metabolism</content>
                              </paragraph>
                              <paragraph>Tigecycline is not extensively metabolized. <content styleCode="italics">In vitro</content> studies with tigecycline using human liver microsomes, liver slices, and hepatocytes led to the formation of only trace amounts of metabolites. In healthy male volunteers receiving <sup>14</sup>C-tigecycline, tigecycline was the primary <sup>14</sup>C-labeled material recovered in urine and feces, but a glucuronide, an N-acetyl metabolite, and a tigecycline epimer (each at no more than 10% of the administered dose) were also present. </paragraph>
                              <paragraph>Tigecycline is a substrate of P-glycoprotein (P-gp) based on an in vitro study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the in vivo disposition of tigecycline is not known.</paragraph>
                           </text>
                           <effectiveTime value="20250505"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s46">
                           <id root="40024baa-ab11-26b5-f787-a3c8b43eb9de"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="italics">Excretion</content>
                           </title>
                           <text>
                              <paragraph>The recovery of total radioactivity in feces and urine following administration of <sup>14</sup>C‑tigecycline indicates that 59% of the dose is eliminated by biliary/fecal excretion, and 33% is excreted in urine. Approximately 22% of the total dose is excreted as unchanged tigecycline in urine. Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline and its metabolites. Glucuronidation and renal excretion of unchanged tigecycline are secondary routes. </paragraph>
                           </text>
                           <effectiveTime value="20250505"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s47">
                           <id root="1ca601fd-a123-c60b-2e87-cb24bd3a3a2f"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Specific</content>
                              <content styleCode="underline">Populations</content>
                           </title>
                           <effectiveTime value="20250505"/>
                           <component>
                              <section ID="s48">
                                 <id root="7d6a15a0-ce58-a5a5-efa6-93df6bd1328c"/>
                                 <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                                 <title>Hepatic Impairment</title>
                                 <text>
                                    <paragraph>In a study comparing 10 patients with mild hepatic impairment (Child Pugh A), 10 patients with moderate hepatic impairment (Child Pugh B), and 5 patients with severe hepatic impairment (Child Pugh C) to 23 age and weight matched healthy control subjects, the single-dose pharmacokinetic disposition of tigecycline was not altered in patients with mild hepatic impairment. However, systemic clearance of tigecycline was reduced by 25% and the half-life of tigecycline was prolonged by 23% in patients with moderate hepatic impairment (Child Pugh B). Systemic clearance of tigecycline was reduced by 55%, and the half-life of tigecycline was prolonged by 43% in patients with severe hepatic impairment (Child Pugh C). Dosage adjustment is necessary in patients with severe hepatic impairment (Child Pugh C) <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s38">8.6</linkHtml>) and Dosage and Administration (<linkHtml href="#s9">2.2</linkHtml>)]</content>. </paragraph>
                                 </text>
                                 <effectiveTime value="20100730"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s49">
                                 <id root="b1663a22-f5b9-6d26-ac33-a9d46c43f8cc"/>
                                 <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                                 <title>Renal Impairment</title>
                                 <text>
                                    <paragraph>A single dose study compared 6 subjects with severe renal impairment (creatinine clearance &lt;30 mL/min), 4 end stage renal disease (ESRD) patients receiving tigecycline 2 hours before hemodialysis, 4 ESRD patients receiving tigecycline 1 hour after hemodialysis, and 6 healthy control subjects. The pharmacokinetic profile of tigecycline was not significantly altered in any of the renally impaired patient groups, nor was tigecycline removed by hemodialysis. No dosage adjustment of tigecycline for injection is necessary in patients with renal impairment or in patients undergoing hemodialysis. </paragraph>
                                 </text>
                                 <effectiveTime value="20100730"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s50">
                                 <id root="9329c5f0-6611-c4f2-7706-9ddadc3a3a2e"/>
                                 <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                                 <title>Geriatric Patients</title>
                                 <text>
                                    <paragraph>No significant differences in pharmacokinetics were observed between healthy elderly subjects (n=15, age 65 to 75; n=13, age &gt;75) and younger subjects (n=18) receiving a single 100-mg dose of tigecycline for injection. Therefore, no dosage adjustment is necessary based on age <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s37">8.5</linkHtml>)]</content>. </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>A single-dose safety, tolerability, and pharmacokinetic study of tigecycline in pediatric patients aged 8 to 16 years who recently recovered from infections was conducted. The doses administered were 0.5, 1, or 2 mg/kg. The study showed that for children aged 12 to 16 years (n = 16) a dosage of 50 mg twice daily would likely result in exposures comparable to those observed in adults with the approved dosing regimen. Large variability observed in children aged 8 to 11 years of age (n = 8) required additional study to determine the appropriate dosage. </paragraph>
                                    <paragraph>A subsequent tigecycline dose-finding study was conducted in 8 to 11 year old patients with cIAI, cSSSI, or CABP. The doses of tigecycline studied were 0.75 mg/kg (n = 17), 1 mg/kg (n = 21), and 1.25 mg/kg (n=20). This study showed that for children aged 8 to 11 years, a 1.2 mg/kg dose would likely result in exposures comparable to those observed in adults resulting with the approved dosing regimen <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#S2.3">2.3</linkHtml>)].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20100730"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s51">
                                 <id root="7338991f-8c6e-8848-f619-568cd4cf0276"/>
                                 <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                                 <title>Gender</title>
                                 <text>
                                    <paragraph>In a pooled analysis of 38 women and 298 men participating in clinical pharmacology studies, there was no significant difference in the mean (±SD) tigecycline clearance between women (20.7±6.5 L/h) and men (22.8±8.7 L/h). Therefore, no dosage adjustment is necessary based on gender. </paragraph>
                                 </text>
                                 <effectiveTime value="20100730"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s52">
                                 <id root="16b386b4-d636-beef-4315-c322d20c23d8"/>
                                 <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                                 <title>Race</title>
                                 <text>
                                    <paragraph>In a pooled analysis of 73 Asian subjects, 53 Black subjects, 15 Hispanic subjects, 190 White subjects, and 3 subjects classified as “other” participating in clinical pharmacology studies, there was no significant difference in the mean (±SD) tigecycline clearance among the Asian subjects (28.8±8.8 L/h), Black subjects (23±7.8 L/h), Hispanic subjects (24.3±6.5 L/h), White subjects (22.1±8.9 L/h), and “other” subjects (25±4.8 L/h). Therefore, no dosage adjustment is necessary based on race. </paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s53">
                           <id root="72d0e4be-d130-99c7-3e2b-b75415fea5c1"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="bold italics underline">Drug Interaction Studies</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Digoxin</content>
                              </paragraph>
                              <paragraph>Tigecycline for injection (100 mg followed by 50 mg every 12 hours) and digoxin (0.5 mg followed by 0.25 mg, orally, every 24 hours) were co-administered to healthy subjects in a drug interaction study. Tigecycline slightly decreased the C<sub>max</sub> of digoxin by 13%, but did not affect the AUC or clearance of digoxin. This small change in C<sub>max</sub> did not affect the steady-state pharmacodynamic effects of digoxin as measured by changes in ECG intervals. In addition, digoxin did not affect the pharmacokinetic profile of tigecycline. Therefore, no dosage adjustment of either drug is necessary when tigecycline for injection is administered with digoxin. </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Warfarin</content>
                              </paragraph>
                              <paragraph>Concomitant administration of tigecycline for injection (100 mg followed by 50 mg every 12 hours) and warfarin (25 mg single-dose) to healthy subjects resulted in a decrease in clearance of R‑warfarin and S‑warfarin by 40% and 23%, an increase in C<sub>max</sub> by 38% and 43% and an increase in AUC by 68% and 29%, respectively. Tigecycline did not significantly alter the effects of warfarin on INR. In addition, warfarin did not affect the pharmacokinetic profile of tigecycline. However, prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin. </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro</content> studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following 6 cytochrome P450 (CYP) isoforms: 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4. Therefore, tigecycline for injection is not expected to alter the metabolism of drugs metabolized by these enzymes. In addition, because tigecycline is not extensively metabolized, clearance of tigecycline is not expected to be affected by drugs that inhibit or induce the activity of these CYP450 isoforms. </paragraph>
                              <paragraph>
                                 <content styleCode="italics">In vitro</content> studies using Caco-2 cells indicate that tigecycline does not inhibit digoxin flux, suggesting that tigecycline is not a P-glycoprotein (P-gp) inhibitor. This <content styleCode="italics">in vitro</content> information is consistent with the lack of effect of tigecycline on digoxin clearance noted in the <content styleCode="italics">in vivo</content> drug interaction study described above. </paragraph>
                              <paragraph>Tigecycline is a substrate of P-gp based on an <content styleCode="italics">in vitro</content> study using a cell line overexpressing P-gp. The potential contribution of P-gp-mediated transport to the <content styleCode="italics">in vivo</content> disposition of tigecycline is not known. Coadministration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline. </paragraph>
                           </text>
                           <effectiveTime value="20200728"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s54">
                     <id root="6e9969b3-5b98-3988-341c-424e313b0842"/>
                     <code code="49489-8" displayName="MICROBIOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>12.4 Microbiology </title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section ID="s55">
                           <id root="60a8fc5f-c42c-ffbf-5523-49d91787bf38"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="bold italics">Mechanism of Action</content>
                           </title>
                           <text>
                              <paragraph>Tigecycline inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. In general, tigecycline is considered bacteriostatic; however, tigecycline for injection has demonstrated bactericidal activity against isolates of <content styleCode="italics">S. pneumoniae</content> and <content styleCode="italics">L. pneumophila</content>. </paragraph>
                           </text>
                           <effectiveTime value="20100730"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s56">
                           <id root="387cb305-e67d-8f82-5aad-741a6d0b47c4"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="bold italics">Resistance</content>
                           </title>
                           <text>
                              <paragraph>To date there has been no cross-resistance observed between tigecycline and other antibacterial drugs. Tigecycline is less affected by the two major tetracycline-resistance mechanisms, ribosomal protection and efflux. Additionally, tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target-site modifications, macrolide efflux pumps or enzyme target changes (e.g., gyrase/topoisomerases). However, some ESBL-producing isolates may confer resistance to tigecycline via other resistance mechanisms. Tigecycline resistance in some bacteria (e.g., <content styleCode="italics">Acinetobacter calcoaceticus-Acinetobacter baumannii</content> complex) is associated with multi-drug resistant (MDR) efflux pumps. </paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s57">
                           <id root="0061e9a0-806f-19b9-dbca-d7f03c908c0d"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="bold italics">Interaction with Other Antimicrobials</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">In vitro</content> studies have not demonstrated antagonism between tigecycline and other commonly used antibacterial drugs. </paragraph>
                              <paragraph>
                                 <content styleCode="italics underline">Antimicrobial Activity </content>
                              </paragraph>
                              <paragraph>Tigecycline has been shown to be active against most isolates of the following microorganisms, both <content styleCode="italics">in vitro</content> and in clinical infections <content styleCode="italics">[see Indications and Usage (<linkHtml href="#s16">1</linkHtml>)]</content>. </paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section ID="G321c360b-a822-461f-8a5a-9ee05f2bd46c">
                           <id root="959718ec-ec3a-1b89-733b-566db59bba53"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>Gram-positive bacteria</title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Enterococcus faecalis</content> (vancomycin-susceptible isolates) </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Staphylococcus aureus</content> (methicillin-susceptible and -resistant isolates) </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Streptococcus agalactiae </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Streptococcus anginosus</content> group (includes <content styleCode="italics">S. anginosus, S. intermedius,</content> and <content styleCode="italics">S. constellatus</content>)</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Streptococcus pneumoniae</content> (penicillin-susceptible isolates) </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Streptococcus pyogenes</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20100730"/>
                        </section>
                     </component>
                     <component>
                        <section ID="G8e12d830-e8a9-4dbf-bf1c-c97a2017247b">
                           <id root="c6250c36-721c-5acf-d376-2a64b4a56632"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>Gram-negative bacteria</title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Citrobacter freundii</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Enterobacter cloacae </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Escherichia coli </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Haemophilus influenzae</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Klebsiella oxytoca </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Klebsiella pneumoniae</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Legionella pneumophila </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20100730"/>
                        </section>
                     </component>
                     <component>
                        <section ID="G46eecdb5-2c8b-4bd0-ba5f-23346d7b695a">
                           <id root="86279726-03ad-5ec2-06b7-907da2471ee7"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>Anaerobic bacteria</title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Bacteroides fragilis</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Bacteroides thetaiotaomicron</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Bacteroides uniformis</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Bacteroides vulgatus</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Clostridium perfringens</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Peptostreptococcus micros</content>
                              </paragraph>
                              <paragraph>The following <content styleCode="italics">in vitro</content> data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an <content styleCode="italics">in vitro</content> minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for tigecycline against isolates of similar genus or organism group. However, the efficacy of tigecycline in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials. </paragraph>
                           </text>
                           <effectiveTime value="20100730"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Gf49f5166-32f6-4b4a-8500-f028d4f4f019">
                           <id root="ac5ba620-2b56-7609-e2f3-be08e0d077fb"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>Gram-positive bacteria</title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Enterococcus avium</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Enterococcus casseliflavus</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Enterococcus faecalis</content> (vancomycin-resistant isolates) </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Enterococcus faecium</content> (vancomycin-susceptible and -resistant isolates) </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Enterococcus gallinarum</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Listeria monocytogenes</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Staphylococcus epidermidis</content> (methicillin-susceptible and -resistant isolates) </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Staphylococcus haemolyticus</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20100730"/>
                        </section>
                     </component>
                     <component>
                        <section ID="G41ee5e50-2477-46b2-882f-45f0b0f078f5">
                           <id root="08334aab-a336-c505-c2bc-ea9e4c9b63fb"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title> Gram-negative bacteria</title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Acinetobacter baumannii* </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Aeromonas hydrophila </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Citrobacter koseri </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Enterobacter aerogenes </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Haemophilus influenzae (ampicillin-resistant) </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Haemophilus parainfluenzae </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Pasteurella multocida </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Serratia marcescens </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Stenotrophomonas maltophilia </content>
                              </paragraph>
                              <paragraph>Anaerobic bacteria </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Bacteroides distasonis </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Bacteroides ovatus </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Peptostreptococcus </content>spp.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Porphyromonas </content>spp.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Prevotella </content>spp.</paragraph>
                           </text>
                           <effectiveTime value="20100730"/>
                        </section>
                     </component>
                     <component>
                        <section ID="G56c2aa9b-46ce-4d47-8d02-039c4c151e53">
                           <id root="96b03ba4-8319-c61e-4521-1bf8b4bb5984"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>Other bacteria </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Mycobacterium abscessus</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Mycobacterium fortuitum</content>
                              </paragraph>
                              <paragraph>*There have been reports of the development of tigecycline resistance in <content styleCode="italics">Acinetobacter</content> infections seen during the course of standard treatment. Such resistance appears to be attributable to an MDR efflux pump mechanism. While monitoring for relapse of infection is important for all infected patients, more frequent monitoring in this case is suggested. If relapse is suspected, blood and other specimens should be obtained and cultured for the presence of bacteria. All bacterial isolates should be identified and tested for susceptibility to tigecycline and other appropriate antimicrobials. </paragraph>
                           </text>
                           <effectiveTime value="20100730"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s64">
                           <id root="bd831e17-11c8-6de4-550a-7bcdb29288d7"/>
                           <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                           <title>
                              <content styleCode="underline">Susceptibility Testing</content>
                           </title>
                           <text>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria, and associated test methods and quality control standards recognized by FDA for this drug, please see https://www.fda.gov/STIC.</paragraph>
                           </text>
                           <effectiveTime value="20250505"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s69">
               <id root="ba7d3bfb-b6b4-a56e-091f-4d1ea6764665"/>
               <code code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20100730"/>
               <component>
                  <section ID="s70">
                     <id root="62efb0c4-06fd-a70d-99ef-5690aa9e6cde"/>
                     <code code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Lifetime studies in animals have not been performed to evaluate the carcinogenic potential of tigecycline. No mutagenic or clastogenic potential was found in a battery of tests, including <content styleCode="italics">in vitro</content> chromosome aberration assay in Chinese hamster ovary (CHO) cells, <content styleCode="italics">in vitro</content> forward mutation assay in CHO cells (HGRPT locus), <content styleCode="italics">in vitro</content> forward mutation assays in mouse lymphoma cells, and <content styleCode="italics">in vivo</content> mouse micronucleus assay. Tigecycline did not affect mating or fertility in rats at exposures up to 5 times the human daily dose based on AUC (28 mcg·hr/mL at 12 mg/kg/day). In female rats, there were no compound-related effects on ovaries or estrous cycles at exposures up to 5 times the human daily dose based on AUC. </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="s71">
                     <id root="2791e5f0-1503-2e26-1752-8fee85b8cfb4"/>
                     <code code="34091-9" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology </title>
                     <text>
                        <paragraph>In two week studies, decreased erythrocytes, reticulocytes, leukocytes, and platelets, in association with bone marrow hypocellularity, have been seen with tigecycline at exposures of 8 times and 10 times the human daily dose based on AUC in rats and dogs, (AUC of approximately 50 and 60 mcg·hr/mL at doses of 30 and 12 mg/kg/day) respectively. These alterations were shown to be reversible after two weeks of dosing. </paragraph>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s72">
               <id root="99f235ad-9e68-a20d-30e3-8d90f732c93a"/>
               <code code="34092-7" displayName="CLINICAL STUDIES SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20200728"/>
               <component>
                  <section ID="G81bcea5a-6e7a-4838-b1b0-2515c0b73074">
                     <id root="b8faf2f2-9325-87e8-6f03-b5e5f3be1df4"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.1 Complicated Skin and Skin Structure Infections </title>
                     <text>
                        <paragraph>Tigecycline for injection was evaluated in adults for the treatment of complicated skin and skin structure infections (cSSSI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 1 and 2). These studies compared tigecycline for injection (100 mg intravenous initial dose followed by 50 mg every 12 hours) with vancomycin (1 g intravenous every 12 hours)/aztreonam (2 g intravenous every 12 hours) for 5 to 14 days. Patients with complicated deep soft tissue infections including wound infections and cellulitis (≥10 cm, requiring surgery/drainage or with complicated underlying disease), major abscesses, infected ulcers, and burns were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients. See Table 4. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 5. </paragraph>
                        <table ID="t5" width="100%">
                           <caption ID="Gdf225343-e308-4fce-a3a4-d5f4b96ac13f">Table 4. Clinical Cure Rates from Two Studies in Complicated Skin and Skin Structure Infections after 5 to 14 Days of Therapy </caption>
                           <colgroup>
                              <col align="left" width="40%"/>
                              <col align="center" width="30%"/>
                              <col align="center" width="30%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>Tigecycline for injection<sup>a </sup>
                                 </th>
                                 <th>Vancomycin/Aztreonam<sup>b </sup>
                                 </th>
                              </tr>
                              <tr>
                                 <th/>
                                 <th>n/N (%) </th>
                                 <th>n/N (%) </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> 100 mg initially, followed by 50 mg every 12 hours<paragraph>
                                       <sup>b</sup> Vancomycin (1 g every 12 hours)/Aztreonam (2 g every 12 hours)</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>Study 1 </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>       CE </td>
                                 <td align="center" valign="middle">165/199 (82.9) </td>
                                 <td align="center" valign="middle">163/198 (82.3) </td>
                              </tr>
                              <tr>
                                 <td>       c-mITT </td>
                                 <td align="center" valign="middle">209/277 (75.5) </td>
                                 <td align="center" valign="middle">200/260 (76.9) </td>
                              </tr>
                              <tr>
                                 <td>Study 2 </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>       CE </td>
                                 <td align="center" valign="middle">200/223 (89.7) </td>
                                 <td align="center" valign="middle">201/213 (94.4) </td>
                              </tr>
                              <tr>
                                 <td styleCode="BOTRULE">       c-mITT </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">220/261 (84.3) </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">225/259 (86.9) </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t6" width="100%">
                           <caption ID="G2e4257fe-e34f-4e2a-b971-0cf691ce901a">Table 5. Clinical Cure Rates By Infecting Pathogen in Microbiologically Evaluable Patients with Complicated Skin and Skin Structure Infections<sup>a</sup>
                           </caption>
                           <colgroup>
                              <col align="left" width="40%"/>
                              <col align="center" width="30%"/>
                              <col align="center" width="30%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>Tigecycline for injection</th>
                                 <th>Vancomycin/Aztreonam</th>
                              </tr>
                              <tr>
                                 <th>Pathogen </th>
                                 <th>n/N (%) </th>
                                 <th>n/N (%) </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> Two cSSSI pivotal studies and two Resistant Pathogen studies<paragraph>
                                       <sup>b</sup> Includes <content styleCode="italics">Streptococcus anginosus</content>, <content styleCode="italics">Streptococcus intermedius</content>, and <content styleCode="italics">Streptococcus constellatus</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <br/>
                                    <content styleCode="italics">Escherichia coli</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle">29/36 (80.6) </td>
                                 <td align="center" valign="middle">26/30 (86.7) </td>
                              </tr>
                              <tr>
                                 <td>
                                    <br/>
                                    <content styleCode="italics">Enterobacter cloacae</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle">10/12 (83.3) </td>
                                 <td align="center" valign="middle">15/15 (100) </td>
                              </tr>
                              <tr>
                                 <td>
                                    <br/>
                                    <content styleCode="italics">Enterococcus faecalis</content> (vancomycin-susceptible only) </td>
                                 <td align="center" valign="middle">15/21 (71.4) </td>
                                 <td align="center" valign="middle">19/24 (79.2) </td>
                              </tr>
                              <tr>
                                 <td>
                                    <br/>
                                    <content styleCode="italics">Klebsiella pneumoniae</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle">12/14 (85.7) </td>
                                 <td align="center" valign="middle">15/16 (93.8) </td>
                              </tr>
                              <tr>
                                 <td>
                                    <br/>Methicillin-susceptible <content styleCode="italics">Staphylococcus aureus</content> (MSSA) <br/>
                                 </td>
                                 <td align="center" valign="middle">124/137 (90.5) </td>
                                 <td align="center" valign="middle">113/120 (94.2) </td>
                              </tr>
                              <tr>
                                 <td>
                                    <br/>Methicillin-resistant <content styleCode="italics">Staphylococcus aureus</content> (MRSA) </td>
                                 <td align="center" valign="middle">79/95 (83.2) </td>
                                 <td align="center" valign="middle">46/57 (80.7) </td>
                              </tr>
                              <tr>
                                 <td>
                                    <br/>
                                    <content styleCode="italics">Streptococcus agalactiae</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle">8/8 (100) </td>
                                 <td align="center" valign="middle">11/14 (78.6) </td>
                              </tr>
                              <tr>
                                 <td>
                                    <br/>
                                    <content styleCode="italics">Streptococcus anginosus</content> grp.<sup>b</sup>
                                 </td>
                                 <td align="center" valign="middle">17/21 (81.0) </td>
                                 <td align="center" valign="middle">9/10 (90.0) </td>
                              </tr>
                              <tr>
                                 <td>
                                    <br/>
                                    <content styleCode="italics">Streptococcus pyogenes</content>
                                    <br/>
                                 </td>
                                 <td align="center" valign="middle">31/32 (96.9) </td>
                                 <td align="center" valign="middle">24/27 (88.9) </td>
                              </tr>
                              <tr>
                                 <td styleCode="BOTRULE">
                                    <br/>
                                    <content styleCode="italics">Bacteroides fragilis</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">7/9 (77.8) </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">4/5 (80.0) </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="G68f47be5-0acb-47e1-84bc-7bff5da0adaf">
                     <id root="9efac531-dac4-0d96-b772-8f9d7daebeed"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.2 Complicated Intra-abdominal Infections </title>
                     <text>
                        <paragraph>Tigecycline for injection was evaluated in adults for the treatment of complicated intra-abdominal infections (cIAI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 1 and 2). These studies compared tigecycline for injection (100 mg intravenous initial dose followed by 50 mg every 12 hours) with imipenem/cilastatin (500 mg intravenous every 6 hours) for 5 to 14 days. Patients with complicated diagnoses including appendicitis, cholecystitis, diverticulitis, gastric/duodenal perforation, intra-abdominal abscess, perforation of intestine, and peritonitis were enrolled in the studies. The primary efficacy endpoint was the clinical response at the TOC visit for the co-primary populations of the microbiologically evaluable (ME) and the microbiologic modified intent-to-treat (m-mITT) patients. See Table 6. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 7. </paragraph>
                        <table ID="t7" width="100%">
                           <caption ID="G258b2e88-5b95-413a-8cc6-6db0d7b70b0c">Table 6. Clinical Cure Rates from Two Studies in Complicated Intra-abdominal Infections after 5 to 14 Days of Therapy </caption>
                           <colgroup>
                              <col align="left" width="40%"/>
                              <col align="center" width="30%"/>
                              <col align="center" width="30%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>Tigecycline for injection<sup>a </sup>
                                 </th>
                                 <th>Imipenem/Cilastatin<sup>b </sup>
                                 </th>
                              </tr>
                              <tr>
                                 <th/>
                                 <th>n/N (%) </th>
                                 <th>n/N (%) </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> 100 mg initially, followed by 50 mg every 12 hours<paragraph>
                                       <sup>b</sup> Imipenem/Cilastatin (500 mg every 6 hours)</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="middle">Study 1 </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td valign="middle">       ME </td>
                                 <td align="center" valign="middle">199/247 (80.6) </td>
                                 <td align="center" valign="middle">210/255 (82.4) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">       m-mITT </td>
                                 <td align="center" valign="middle">227/309 (73.5) </td>
                                 <td align="center" valign="middle">244/312 (78.2) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">Study 2 </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td valign="middle">       ME </td>
                                 <td align="center" valign="middle">242/265 (91.3) </td>
                                 <td align="center" valign="middle">232/258 (89.9) </td>
                              </tr>
                              <tr>
                                 <td styleCode="BOTRULE" valign="middle">       m-mITT </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">279/322 (86.6) </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">270/319 (84.6) </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t8" width="100%">
                           <caption ID="G8034fc4a-efe6-42a7-b036-7dbdfba9094d">Table 7. Clinical Cure Rates By Infecting Pathogen in Microbiologically Evaluable Patients with Complicated Intra-abdominal Infections<sup>a</sup>
                           </caption>
                           <colgroup>
                              <col align="left" width="40%"/>
                              <col align="center" width="30%"/>
                              <col align="center" width="30%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>Tigecycline for injection</th>
                                 <th>Imipenem/Cilastatin</th>
                              </tr>
                              <tr>
                                 <th>Pathogen </th>
                                 <th>n/N (%) </th>
                                 <th>n/N (%) </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> Two cIAI pivotal studies and two Resistant Pathogen studies<paragraph>
                                       <sup>b</sup> Includes <content styleCode="italics">Streptococcus anginosus</content>, <content styleCode="italics">Streptococcus intermedius</content>, and <content styleCode="italics">Streptococcus constellatus</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Citrobacter freundii</content>
                                 </td>
                                 <td align="center" valign="middle">12/16 (75.0) </td>
                                 <td align="center" valign="middle">3/4 (75.0) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Enterobacter cloacae</content>
                                 </td>
                                 <td align="center" valign="middle">15/17 (88.2) </td>
                                 <td align="center" valign="middle">16/17 (94.1) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Escherichia coli</content>
                                 </td>
                                 <td align="center" valign="middle">284/336 (84.5) </td>
                                 <td align="center" valign="middle">297/342 (86.8) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Klebsiella oxytoca</content>
                                 </td>
                                 <td align="center" valign="middle">19/20 (95.0) </td>
                                 <td align="center" valign="middle">17/19 (89.5) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Klebsiella pneumoniae</content>
                                 </td>
                                 <td align="center" valign="middle">42/47 (89.4) </td>
                                 <td align="center" valign="middle">46/53 (86.8) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Enterococcus faecalis</content>
                                 </td>
                                 <td align="center" valign="middle">29/38 (76.3) </td>
                                 <td align="center" valign="middle">35/47 (74.5) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">Methicillin-susceptible</td>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Staphylococcus aureus</content> (MSSA)</td>
                                 <td align="center" valign="middle">26/28 (92.9) </td>
                                 <td align="center" valign="middle">22/24 (91.7) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">Methicillin-resistant</td>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Staphylococcus aureus</content> (MRSA) </td>
                                 <td align="center" valign="middle">16/18 (88.9) </td>
                                 <td align="center" valign="middle">1/3 (33.3) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Streptococcus anginosus</content> grp.<sup>b</sup>
                                 </td>
                                 <td align="center" valign="middle">101/119 (84.9) </td>
                                 <td align="center" valign="middle">60/79 (75.9) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Bacteroides fragilis</content>
                                 </td>
                                 <td align="center" valign="middle">68/88 (77.3) </td>
                                 <td align="center" valign="middle">59/73 (80.8) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Bacteroides thetaiotaomicron</content>
                                 </td>
                                 <td align="center" valign="middle">36/41 (87.8) </td>
                                 <td align="center" valign="middle">31/36 (86.1) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Bacteroides uniformis</content>
                                 </td>
                                 <td align="center" valign="middle">12/17 (70.6) </td>
                                 <td align="center" valign="middle">14/16 (87.5) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Bacteroides vulgatus</content>
                                 </td>
                                 <td align="center" valign="middle">14/16 (87.5) </td>
                                 <td align="center" valign="middle">4/6 (66.7) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">
                                    <content styleCode="italics">Clostridium perfringens</content>
                                 </td>
                                 <td align="center" valign="middle">18/19 (94.7) </td>
                                 <td align="center" valign="middle">20/22 (90.9) </td>
                              </tr>
                              <tr>
                                 <td styleCode="BOTRULE" valign="middle">
                                    <content styleCode="italics">Peptostreptococcus micros</content>
                                 </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">13/17 (76.5) </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">8/11 (72.7) </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20100730"/>
                  </section>
               </component>
               <component>
                  <section ID="Gad5c8d74-fed1-4be4-92ca-c578768ad097">
                     <id root="88a7242c-d681-221a-bbb8-663bb4f8f9c3"/>
                     <code code="42229-5" displayName="SPL UNCLASSIFIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
                     <title>14.3 Community-Acquired Bacterial Pneumonia </title>
                     <text>
                        <paragraph>Tigecycline for injection was evaluated in adults for the treatment of community-acquired bacterial pneumonia (CABP) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 1 and 2). These studies compared tigecycline for injection (100 mg intravenous initial dose followed by 50 mg every 12 hours) with levofloxacin (500 mg intravenous every 12 or 24 hours). In Study 1, after at least 3 days of intravenous therapy, a switch to oral levofloxacin (500 mg daily) was permitted for both treatment arms. Total therapy was 7 to 14 days. Patients with community-acquired bacterial pneumonia who required hospitalization and intravenous therapy were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co‑primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c‑mITT) patients. See Table 8. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 9. </paragraph>
                        <table ID="t9" width="100%">
                           <caption ID="G4b3fb64c-2553-4ad8-b460-33a97440afd6">Table 8. Clinical Cure Rates from Two Studies in Community-Acquired Bacterial Pneumonia after 7 to 14 Days of Total Therapy </caption>
                           <colgroup>
                              <col align="left" width="40%"/>
                              <col align="center" width="20%"/>
                              <col align="center" width="20%"/>
                              <col align="center" width="20%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>Tigecycline for injection<sup>a </sup>
                                 </th>
                                 <th>Levofloxacin<sup>b </sup>
                                 </th>
                                 <th/>
                              </tr>
                              <tr>
                                 <th/>
                                 <th>n/N (%) </th>
                                 <th>n/N (%) </th>
                                 <th>95% CI<sup>c</sup>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="4">
                                    <sup>a</sup> 100 mg initially, followed by 50 mg every 12 hours<paragraph>
                                       <sup>b</sup> Levofloxacin (500 mg intravenous every 12 or 24 hours)</paragraph>
                                    <paragraph>
                                       <sup>c</sup> 95% confidence interval for the treatment difference</paragraph>
                                    <paragraph>
                                       <sup>d</sup> After at least 3 days of intravenous therapy, a switch to oral levofloxacin (500 mg daily) was permitted for both treatment arms in Study 1.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="middle">Study 1<sup>d</sup>
                                 </td>
                                 <td align="center"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td valign="middle">       CE </td>
                                 <td align="center">125/138 (90.6)</td>
                                 <td align="center" valign="middle">136/156 (87.2) </td>
                                 <td align="center" valign="middle">(-4.4, 11.2) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">       c-mITT </td>
                                 <td align="center">149/191 (78)</td>
                                 <td align="center" valign="middle">158/203 (77.8) </td>
                                 <td align="center" valign="middle">(-8.5, 8.9) </td>
                              </tr>
                              <tr>
                                 <td valign="middle">Study 2 </td>
                                 <td align="center"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td valign="middle">       CE </td>
                                 <td align="center">128/144 (88.9)</td>
                                 <td align="center" valign="middle">116/136 (85.3) </td>
                                 <td align="center" valign="middle">(-5.0, 12.2) </td>
                              </tr>
                              <tr>
                                 <td styleCode="BOTRULE" valign="middle">       c-mITT </td>
                                 <td align="center">170/203 (83.7)</td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">163/200 (81.5) </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">(-5.6, 10.1) </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t10" width="100%">
                           <caption ID="Ge354004b-492e-4424-acdb-268555f76ac4">Table 9. Clinical Cure Rates By Infecting Pathogen in Microbiologically Evaluable Patients with Community-Acquired Bacterial Pneumonia<sup>a</sup>
                           </caption>
                           <colgroup>
                              <col align="left" width="40%"/>
                              <col align="center" width="30%"/>
                              <col align="center" width="30%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>Tigecycline for injection</th>
                                 <th>Levofloxacin</th>
                              </tr>
                              <tr>
                                 <th>Pathogen </th>
                                 <th>n/N (%) </th>
                                 <th>n/N (%) </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3">
                                    <sup>a</sup> Two CABP studies<paragraph>
                                       <sup>b</sup> Includes cases of concurrent bacteremia [cure rates of 20/22 (90.9%) versus 13/18 (72.2%) for tigecycline for injection and levofloxacin respectively] </paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="italics">Haemophilus influenzae</content>
                                 </td>
                                 <td align="center" valign="middle">14/17 (82.4) </td>
                                 <td align="center" valign="middle">13/16 (81.3) </td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="italics">Legionella pneumophila</content>
                                 </td>
                                 <td align="center" valign="middle">10/10 (100.0) </td>
                                 <td align="center" valign="middle">6/6 (100.0) </td>
                              </tr>
                              <tr>
                                 <td styleCode="BOTRULE">
                                    <content styleCode="italics">Streptococcus pneumoniae</content>
                                 </td>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td>(penicillin-susceptible only)<sup>b</sup>
                                 </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">44/46 (95.7) </td>
                                 <td align="center" styleCode="BOTRULE" valign="middle">39/44 (88.6) </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>To further evaluate the treatment effect of tigecycline, a post-hoc analysis was conducted in CABP patients with a higher risk of mortality, for whom the treatment effect of antibacterial drugs is supported by historical evidence. The higher-risk group included CABP patients from the two studies with any of the following factors: </paragraph>
                        <list ID="Ga00b12ea-9654-4e85-a3b4-859ec7348768" listType="unordered" styleCode="Disc">
                           <item>Age ≥50 years </item>
                           <item>PSI score ≥3 </item>
                           <item>
                              <content styleCode="italics">Streptococcus pneumoniae</content> bacteremia </item>
                        </list>
                        <paragraph>The results of this analysis are shown in Table 10. Age ≥50 was the most common risk factor in the higher-risk group. </paragraph>
                        <table ID="t11" width="100%">
                           <caption ID="G27e24559-6ed6-49f7-a922-9571f94945ca">Table 10. Post-hoc Analysis of Clinical Cure Rates in Patients with Community-Acquired Bacterial Pneumonia Based on Risk of Mortality<sup>a</sup>
                           </caption>
                           <colgroup>
                              <col align="left" width="25%"/>
                              <col align="center" width="25%"/>
                              <col align="center" width="25%"/>
                              <col align="center" width="25%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th/>
                                 <th>Tigecycline for injection</th>
                                 <th>Levofloxacin</th>
                                 <th/>
                              </tr>
                              <tr>
                                 <th/>
                                 <th>n/N (%) </th>
                                 <th>n/N (%) </th>
                                 <th>95% CI<sup>b</sup>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="4">
                                    <sup>a</sup> Patients at higher risk of death include patients with any one of the following: ≥50 year of age; PSI score ≥3; or bacteremia due to <content styleCode="italics">Streptococcus pneumoniae</content>
                                    <paragraph>
                                       <sup>b</sup> 95% confidence interval for the treatment difference</paragraph>
                                    <paragraph>
                                       <sup>c</sup> After at least 3 days of intravenous therapy, a switch to oral levofloxacin (500 mg daily) was permitted for both treatment arms in Study 1.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>Study 1<sup>c</sup>
                                 </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>     CE </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>     Higher risk </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>       Yes </td>
                                 <td align="center" valign="middle">93/103 (90.3) </td>
                                 <td align="center" valign="middle">84/102 (82.4) </td>
                                 <td align="center" valign="middle">(-2.3, 18.2) </td>
                              </tr>
                              <tr>
                                 <td>       No </td>
                                 <td align="center" valign="middle">32/35 (91.4) </td>
                                 <td align="center" valign="middle">52/54 (96.3) </td>
                                 <td align="center" valign="middle">(-20.8, 7.1) </td>
                              </tr>
                              <tr>
                                 <td>     c-mITT </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>     Higher risk </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>       Yes </td>
                                 <td align="center" valign="middle">111/142 (78.2) </td>
                                 <td align="center" valign="middle">100/134 (74.6) </td>
                                 <td align="center" valign="middle">(-6.9, 14) </td>
                              </tr>
                              <tr>
                                 <td>       No </td>
                                 <td align="center" valign="middle">38/49 (77.6) </td>
                                 <td align="center" valign="middle">58/69 (84.1) </td>
                                 <td align="center" valign="middle">(-22.8, 8.7) </td>
                              </tr>
                              <tr>
                                 <td>Study 2 </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>     CE </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>     Higher risk </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>       Yes </td>
                                 <td align="center" valign="middle">95/107 (88.8) </td>
                                 <td align="center" valign="middle">68/85 (80) </td>
                                 <td align="center" valign="middle">(-2.2, 20.3) </td>
                              </tr>
                              <tr>
                                 <td>       No </td>
                                 <td align="center" valign="middle">33/37 (89.2) </td>
                                 <td align="center" valign="middle">48/51 (94.1) </td>
                                 <td align="center" valign="middle">(-21.1, 8.6) </td>
                              </tr>
                              <tr>
                                 <td>     c-mITT </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>     Higher risk </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                                 <td align="center" valign="middle"> </td>
                              </tr>
                              <tr>
                                 <td>       Yes </td>
                                 <td align="center" valign="middle">112/134 (83.6) </td>
                                 <td align="center" valign="middle">93/120 (77.5) </td>
                                 <td align="center" valign="middle">(-4.2, 16.4) </td>
                              </tr>
                              <tr>
                                 <td>       No </td>
                                 <td align="center" valign="middle">58/69 (84.1) </td>
                                 <td align="center" valign="middle">70/80 (87.5) </td>
                                 <td align="center" valign="middle">(-16.2, 8.8) </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20200728"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Ga3642138-00aa-4f16-96de-1ea39c39bd24">
               <id root="522ebd32-82fd-6149-34ad-4aaeac608b32"/>
               <code code="34069-5" displayName="HOW SUPPLIED SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Tigecycline for injection, USP is supplied in a single-dose 5 mL glass vial, each containing 50 mg tigecycline, USP lyophilized powder for reconstitution. </paragraph>
                  <paragraph>Supplied: </paragraph>
                  <paragraph>10 single-dose vials in one box. NDC 60505-6098-1</paragraph>
                  <paragraph>Prior to reconstitution, tigecycline for injection, USP should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature.] The reconstituted solution of tigecycline for injection, USP may be stored at room temperature (not to exceed 25°C/77°F) for up to 24 hours (up to 6 hours in the vial and the remaining time in the intravenous bag) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s8">2.5</linkHtml>)]</content>.</paragraph>
               </text>
               <effectiveTime value="20250505"/>
            </section>
         </component>
         <component>
            <section ID="Gc9161ea4-590f-4c94-92c2-e633855d667e">
               <id root="4fc23a4a-f4de-cba8-1faf-5c271a0e176b"/>
               <code code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION" codeSystem="2.16.840.1.113883.6.1"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Tooth Discoloration and Inhibition of Bone Growth</content>   </paragraph>
                  <paragraph> Advise pregnant women that tigecycline for injection may cause permanent discoloration of deciduous teeth and reversible inhibition of bone growth when administered during the second and third trimesters of pregnancy <content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#s20">5.7</linkHtml>, 5.8) and Use in Specific Populations (8.1, 8.4)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>   </paragraph>
                  <paragraph> Advise a woman not to breastfeed for longer than 3 weeks while taking tigecycline for injection because of the lack of data on effects due to prolonged breastfeeding, and the theoretical risk of dental discoloration and inhibition of bone growth. Women may also consider reducing infant exposure through pumping and discarding breastmilk during and for 9 days after the last dose of tigecycline <content styleCode="italics"> [see Use in Specific Populations (<linkHtml href="#_f8b8cb58-2984-8d4e-25ce-209e1c829a66">8.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Diarrhea</content>
                  </paragraph>
                  <paragraph>Advise patients, their families, or caregivers that diarrhea is a common problem caused by antibacterial drugs, including tigecycline for injection. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, advise patients to contact his or her healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s21">5.9</linkHtml>)]. </content>   </paragraph>
                  <paragraph>
                     <content styleCode="underline"> Development of Resistance </content>   </paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs including tigecycline for injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When tigecycline for injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by tigecycline for injection or other antibacterial drugs in the future.</paragraph>
                  <paragraph>This product’s labeling may have been updated. For the most recent prescribing information, please visit www.apotex.com.</paragraph>
                  <table width="60%">
                     <col align="left" width="40%"/>
                     <col align="left" width="20%"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Manufactured by:</content>
                           </td>
                           <td>
                              <content styleCode="bold">Manufactured for:</content>
                           </td>
                        </tr>
                        <tr>
                           <td>Gland Pharma Limited, India.</td>
                           <td>Apotex Corp.</td>
                        </tr>
                        <tr>
                           <td>ML No.<br/> 103/AP/RR/97/F/R</td>
                           <td>Weston, Florida<br/> 33326</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Rev. 1</paragraph>
                  <paragraph>Revised: 05/2025</paragraph>
               </text>
               <effectiveTime value="20250505"/>
            </section>
         </component>
         <component>
            <section ID="_4ce1aa00-8122-1317-6239-ef6907f0144d">
               <id root="a25a6a6a-95da-4928-fcbd-62345c8d5ded"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION</title>
               <text>
                  <paragraph>Tigecycline for injection 50 mg/vial - Vial Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM541912986681"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241001"/>
            </section>
         </component>
         <component>
            <section ID="_346ba29d-28a2-5d1d-bf82-c5054059d3d2">
               <id root="44dcc3fc-2daf-fbb5-c2cb-3c9b414d260c"/>
               <code code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL" codeSystem="2.16.840.1.113883.6.1"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL SECTION</title>
               <text>
                  <paragraph>Tigecycline for injection 50 mg/vial - Carton Label</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM446828213536"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241001"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>